Biocorp: Novo Nordisk acquires a controlling stake
Completion of the acquisition of this controlling block and of the shares held by minority shareholders, together representing 64.4% of the capital and 75.3% of the voting rights, is subject to obtaining the usual regulatory approvals.
As a result of the proposed transaction, Novo Nordisk will file a simplified tender offer with the AMF in the third quarter of 2023, at a price that would value 100% of Biocorp at €154.4 million.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction